Sign in
CINGW Stock Price, Chart, Stats & News
Cingulate Inc.
Save
161,410
Market cap
–
Current P/E
–
Forward P/E
CINGW chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -148.94% |
ROE | -515.34% |
D/E | 3.50x |
Interest coverage ratio | 14.65x |
CINGW valuation
P/E | – |
P/S | – |
P/B | 13.83x |
P/CF | 0.00x |
P/FCF | 0.00x |
P/OCF | 0.00x |
PEG | -0.09x |
EV multiple | -1.96x |
About
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions. Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders.
Similar securities
Based on sector and market capitalization
Report issue